Highlights

• Ansell rose 0.58% to $42.545 on 4 September 2026

• FY2026 final Dividend Exchange Rate set at US$0.415 per share

• Erik Van den Enden appointed as Chief Financial Officer in September 2026

• New CFO appointment adds executive Leadership following the FY2026 reporting period

Ansell Ltd (ASX:ANN) edged higher by 0.58% to $42.545 on 4 September 2026, with investor attention turning to two notable corporate developments: the confirmation of its FY2026 final dividend and the appointment of a new Chief Financial Officer.

About the Company

Ansell is a global leader in protection solutions, specialising in gloves, protective clothing and safety solutions for industrial, medical and consumer markets. Headquartered in Melbourne, the company manufactures and sells products in over 100 countries. Ansell serves industries including healthcare, chemical, food processing and automotive, and has operations in Manufacturing facilities across Asia, Europe and North America. The company has undertaken significant portfolio restructuring in recent years, divesting its sexual wellness Business to focus on its core protection businesses.

Key Developments

Ansell has disclosed its FY2026 final dividend exchange rate, with the applicable US-dollar dividend rate set at US$0.415 per share. In September 2026, the company also announced the appointment of Erik Van den Enden as Chief Financial Officer. The appointment adds a new executive finance leader following the company's FY2026 reporting period.

Key Catalysts to Watch

• FY2027 Earnings guidance and strategic priorities under the new CFO

• Volume recovery in healthcare glove markets following Pandemic normalisation

• Progress on cost efficiency and Margin improvement programs

• Any M&A activity or portfolio restructuring announcements

Risks

• Softening in global Demand for medical and industrial protective equipment

• Raw material cost pressures affecting margins

• Competition from low-cost glove manufacturers in Asia

• Integration risk if new CFO drives strategic changes

Conclusion

Ansell's 0.58% gain on 4 September reflects steady investor confidence in a business that continues to execute through a post-pandemic normalisation period. The appointment of a new CFO and confirmation of the FY2026 dividend provide small positive signals. Investors will be watching how the incoming finance chief shapes strategy and whether the business can sustain margin recovery in healthcare and industrial protection markets. Ansell remains a solid, if quietly positioned, ASX healthcare name.